Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming ...

Eli Lilly stock rises more than 11% as weight loss pill orforglipron shows promising trial results, raising hopes for a ...

Rival companies trying to develop oral weight-loss candidates include Novo Nordisk, which has an oral formulation of ...

JNJ beats first-quarter estimates for earnings and sales. PFE ends the development of the weight loss pill danuglipron.

Eli Lilly’s recent announcement of the success of its daily obesity pill, orforglipron, in the first late-stage trial has generated significant buzz in the pharmaceutical industry. The trial, which ...

Seeking Alpha analyst Stephen Ayers shares his views on which weight-loss drug stock looks most attractive for investors ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...

Jefferies analyst Benjamin Jackson CFA maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...